RYTM News and Press, Rhythm Pharmaceuticals Inc. From 06/28/20

Rhythm Pharmaceuticals Reports Positive Phase 2 Data for Setmelanotide Rhythm Pharmaceuticals Inc. ( RYTM ) announced interim data from its Phase 2 study of Setmelanotide. Under this trial, healthy obese people were administered the weekly formulation of the drug candidate. The trial wa...

Rhythm Pharmaceuticals (NASDAQ: RYTM ) announces positive preliminary data from a Phase 2 clinical trial evaluating once-weekly setmelanotide in healthy obese volunteers. More news on: Rhythm Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

-- Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation – -- Both weekly and daily formulations of setmelanotide were observed to be safe and well-tolerated – -- Pharmacokinetics analysis showed weekly formula...

BOSTON, May 26, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will participate in ...

– FDA grants Priority Review of application and sets PDUFA goal date of November 27, 2020 – BOSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing thera...

BOSTON, May 05, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Interim Chief Executive O...

Rhythm Pharmaceuticals (NASDAQ: RYTM ): Q1 GAAP EPS of -$0.78 beats by $0.02 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Completed rolling NDA submission to FDA for setmelanotide in POMC and LEPR deficiency obesities; on track to submit MAA to EMA in the second quarter of 2020 – -- Received Orphan Drug Designation from FDA for setmelanotide for the treatment of Alström syndrome -- -- ...

BOSTON, April 07, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Interim Chief Executive...

 Hunter Smith, Chief Financial Officer, appointed Interim Chief Executive Officer following completion of NDA submission to FDA    Precautionary measures in place to mitigate impact of COVID-19 on clinical programs  BOSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Rhyt...